This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Lengthy Neurological Diagnosis Delay May Impact Patients, Survey Shows

Stocks in this article: GE

According to a new survey, some patients with major neurological diseases believe they were not properly diagnosed for more than a year, potentially leading to patient anxiety, unnecessary or inappropriate treatments, delays in appropriate care, and added costs to the global healthcare system. The opinion survey examined the impact of diagnosis delays in the most prominent neurological disorders: Alzheimer’s (AD), Parkinson’s (PD) and Multiple Sclerosis (MS).

The survey, commissioned by GE Healthcare and conducted by Praxis Research, Inc., reflects opinions of physicians and patients in the US, UK, Germany and France. A total of 240 physicians, consisting of hospital and office-based neurologists and psychiatrists (UK-only) participated. A total of 101 patients with Multiple Sclerosis, Parkinson’s disease or Alzheimer’s disease participated.

According to the survey, median times in patient estimates of time to diagnosis from onset of symptoms were seven to 12 months across all disease states. AD was diagnosed fastest, on average (12.7 months), followed by MS (13.6 months) and PD (14.7 months). This time included the time that patients waited (from less than a week to more than a year) before consulting a physician. Physicians who participated in the survey said approximately a third of patients could or should have been diagnosed faster and may suffer unnecessarily as a result of delay.

“It is not acceptable that some patients with progressive neurological disorders have to wait so long before they receive a diagnosis, during which time many face the possibility of receiving the wrong or unnecessary treatment and needing to consult with multiple healthcare professionals, “ said Gabrielle Silver, MD and Head of Neuroscience Marketing at GE Healthcare. “This delay can be stressful to patients, and can also cost the health economy millions of dollars in unnecessary use of resources. Patients and their families should not have to tolerate lengthy delays.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs